EAS Newsletter April 23, 2024


Join the record number of attendees already registered!

Last 2 days to get a regular registration rate! Join the record number of attendees already registered and take advantage of significant savings of up to 225€ by registering early. Act now to ensure your participation in this enriching experience!

Register for the EAS Congress 2024


What are challenges in achieving control of lipid disorders in LatAm?

Atherosclerotic cardiovascular diseases (ASCVD), including myocardial infarction, stroke, and peripheral arterial disease, remain major causes of death in LATAM. The primary strategy for preventing ASCVD involves averting the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall. Extensive, well-designed, placebo-controlled studies have demonstrated that lowering LDL cholesterol levels reduces cardiovascular events.

Given the significant number of patients requiring lipid-lowering therapy, a crucial question arises: Are we effectively treating LDL cholesterol levels to attain the desired goals?

In this webinar, we will delve into dyslipidemia as a cardiovascular risk in LATAM. We will discuss LDL cholesterol goals recommended by recent guidelines, focusing on the barriers hindering the achievement of these goals. Moreover, we will emphasize the necessity of identifying the main barriers to getting patients to their goals and controlling cardiovascular risk factors to prevent major cardiovascular events. Additionally, the webinar will explore potential solutions to overcome these challenges.

Register for the second webinar of the series by clicking on the button below:

To the registration page


Submit your abstract for 47th European Lipoprotein Club Meeting and participate in the perfect mix of science, development & fun!

If you are interested in lipids, lipoproteins, and metabolism, you should plan to attend the 47th Meeting of the EAS European Lipoprotein Club (ELC) during the first half of September. Don’t miss the opportunity to participate in this perfect mix of science, professional development, and fun! Make sure to submit your abstract by April 24, 2024:

To submit your abstract


Recent issue highlights – January & February 2024

Lipoprotein(a) (Lp(a)) is an important, mostly genetically determined risk factor for atherosclerotic cardiovascular diseases (ASCVD) as well as aortic valve calcification. Lp(a) experienced several waves of scientific and medical attention: a first one when it was discovered by Kare Berg as a genetically determined trait associated with coronary heart disease; a second one in the late 1980s and early 1990s when the apolipoprotein(a) gene was cloned and its variable number of repeat polymorphism was identified as the basis of the strong genetic determination, and cohort studies showed the independent association of elevated Lp(a) with increased risk of incident ASCVDs; a third one when genome wide association studies and Mendelian randomization studies established the LPA gene as a genetically causal risk factor of ASCVDs; and a forth one upon development of antisense oligonucleotides and siRNAs towards therapy to lower Lp(a) plasma levels. The current strong attention is also reflected by high numbers of submissions to Atherosclerosis addressing Lp(a). Some of the recently published papers are summarized below.

January issue vol. 388

February issue vol. 389


EAS Calendar – April-May 2024

From insightful webinars to groundbreaking announcements, this section is your gateway to staying connected and up-to-date with the latest developments within the EAS Society.

  • April 25, Regular registration fee deadline for the EAS Congress 2024
  • April 30-May 3, Postgraduate Course in Cardiometabolic Medicine
  • May 8, LatAm-EAS: Global Epidemic of Obesity and Cardiovascular Disease: The heart of the problem
  • May 26-29, EAS Congress 2024, Lyon, France